GD Pharma currently manufactures products which are unregistered therapeutic goods
and are available in Australia under the Schedule 5A of the Therapeutic Goods Regulations 1990 of Australia.
GD Pharma is passionate about improving the lives of those suffering pain, while also finding innovative ways for medical professionals to deliver these treatments. Our products for pain include our unique design for a nasal delivery system to ease to administration of pain medications in emergency situations.
GD Pharma has been involved in manufacture for multiple clinical trials studying drugs used in treatment of addiction. We also manufacture intravenous products for the treatment of both opioid addiction and benzodiazepine overdose.
There is sufficient reason to believe that medicinal cannabis can help in cases of muscle spasms and some forms of epilepsy, nausea associated with chemotherapy and chronic pain. With the new regulatory changes allowing medicinal cannabinoids, GD Pharma is proud to hold TGA Licencing for manufacture of products containing cannabinoids. We are currently researching improved methods for oral delivery of cannabinoids.
If you are an Australian Health Practitioner who would like to learn more about the products we currently manufacture under Schedule 5A, please provide your details below and we will send you details to access the portal